Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user is documenting their hair loss treatment using 2.5mg minoxidil, 1.25mg finasteride, and 2.5mg biotin, planning to update monthly. Another user advises taking comprehensive scalp photos for better progress tracking.

The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

RU58841 is used to eliminate scalp itch. Users discuss difficulty finding reliable and affordable sources.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

Breezula may be released around 2027 but its effectiveness for advanced thinning is uncertain, and it might be expensive. Users discuss alternatives like low-dose topical finasteride and combining it with Breezula for better results.

The user reported positive hair regrowth results after six months of using 0.5 mg finasteride and nanoxidil, despite experiencing initial side effects like testicular pain and changes in libido. They noted that nanoxidil was chosen over minoxidil due to less scalp irritation.

A 20-year-old has been using 1mg of dutasteride daily, caffeine shampoo, Nizoral shampoo 2-4 times a week, and pumpkin seed pills for hair growth, noticing regrowth since October. Initial shedding occurred, but improvements are felt, especially at the back of the hair.

The conversation discusses experiences with PTD-DBM for hair loss treatment. It also mentions using Minoxidil, finasteride, and RU58841.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.

The conversation humorously discusses hair loss treatments, specifically finasteride and minoxidil. Users joke about side effects and suggest using seaweed for white hair.

Beta blockers may cause hair thinning as a side effect. The user is concerned about this and seeks others' experiences with hair loss while using beta blockers.

A user shared progress pictures showing improvement from NW 6 to NW 2 after four months of treatment. They are considering using exosomes to further reverse hair miniaturization.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

Nanoxidil, a minoxidil derivative, is being discussed as a potential hair loss treatment. Users are curious about its effectiveness and side effects compared to minoxidil, with some noting it includes additional ingredients like caffeine.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

The conversation discusses the effects of B5 (Pantothenic acid), B7 (Biotin), and B12 on hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

The conversation humorously discusses hair loss treatments, mentioning scalp massage, minoxidil, and the ineffectiveness of devices like the "Gr0wBand." It highlights the role of androgens in hair loss and suggests that increased blood flow from massage may not significantly impact hair growth.

The conversation discusses additional treatments for hair loss beyond finasteride, minoxidil, and ketoconazole shampoo, including multivitamins, vitamin D, BioSil drops, castor oil, biotin, and saw palmetto. Users share their experiences and side effects with these treatments.

The conversation discusses hair regrowth possibilities using finasteride, minoxidil, microneedling, and dutasteride, with the user experiencing improvement from NW4 to NW2. Achieving NW0 is deemed unrealistic, but further regrowth may be possible with patience and potentially a hair transplant.